ISSN 0031-6970
6 papers in the library · 371 citations · publishing 2003-2025
European Journal of Clinical Pharmacology December 22, 2025 Claudia Pisanu, Shungo Imai, Masami Tsuchiya et al. 3 citations
Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.
European Journal of Clinical Pharmacology July 1, 2025 Lingjing Yuan, Jianping He, Xiangyu Li 3 citations
Dextromethorphan/bupropion (D/B) is an innovative pharmacological treatment for major depressive disorder. Nevertheless, the current evidence regarding the safety profile of D/B is predominantly derived from clinical trials, thus hindering the timely updating of adverse event (AE) data for this medication. Therefore, this study conducted data mining and analysis of AE signals (especially for...
European Journal of Clinical Pharmacology October 27, 2021 T. Lima, M. B. Visacri, P. M. Aguiar 38 citations
To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled trials on the use of ketamine and esketamine in adult patients with depression. Two authors independently...
European Journal of Clinical Pharmacology December 2, 2017 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 15 citations
Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of α 1 -adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms...
European Journal of Clinical Pharmacology May 1, 2012 David M Wood, Susannah Davies, Malgorzata Puchnarewicz et al.
Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a "bladder safe" derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals...
European Journal of Clinical Pharmacology September 1, 2003 Mats Bergstr�m, A. Grahn�n, B. L�ngstr�m 312 citations
The realisation that new chemical entities under development as drug candidates fail in three of four cases in clinical trials, together with increased costs and increased demands of reducing preclinical animal experiments, have promoted concepts for improvement of early screening procedures in humans. Positron emission tomography (PET) is a non-invasive imaging technology, which makes it...